We are thrilled to report that we have an approved Pilot version of the Patient Reported Impact of Dermatological Diseases (PRIDD) measure which consists of 22 questions derived directly from patients through a scientifically rigorous process. Having just completed the validation of the Pilot PRIDD measure through cognitive testing interviews with patients, psychometric testing will begin with patients around the world in November. We will be reaching out to select patient organizations across a broad cross-section of diseases and regions in the final months of 2021 and Q2 2022 to encourage their patients to answer questionnaires that will allow researchers to test how PRIDD performs and finalize scoring. Join us for our upcoming webinar, "Changing the Way the World Sees Dermatology Through the GRIDD Project", taking place on September 22 at 10:30 - 11:30 (EDT) | 16:30 - 17:30 (CEST)*. This event is being co-hosted by GlobalSkin and the International League of Dermatological Societies (ILDS). Our expert presenters will be Jennifer Austin, GlobalSkin, CEO (Interim), and Rachael Pattinson, GRIDD Researcher, PhD Candidate, Cardiff University. We will also be joined by Bill McCue, patient leader and founder of the PRP Alliance and Dr. Ramesh Bhat, Board Member of the International League of the Dermatological Societies (ILDS) and the Vice-Chair of the ILDS Patients’ Organisations Working Group (POWG). Learn more about the GRIDD project and the role of patient organizations and physicians in Phase 4 - Psychometric Testing of PRIDD, taking place in November.
Check out a recent article published on the ILDS website about GRIDD. |